Letrozole Therapy Beginning Long After Stopping Tamoxifen Still Offers Preventive Benefits For Breast Cancer
Treatment with the aromatase inhibitor letrozole (Femara) can reduce the risk of breast cancer recurrence even when initiated one to seven years after a course of tamoxifen therapy. The results of a study involving women originally in the placebo arm of an international trial of letrozole will appear in the Journal of Clinical Oncology and are receiving early online release.
More: continued here
Filed under: Breast Cancer on March 15th, 2008